#BMS #Cobenfy #schizophrenia #psychiatry Biotech Executive, Thought Leader & Creator | Diagnostics Executive | Microfluidics & Immunoassay Innovation | FDA Strategy Led EUA 230055, EUA 240006 & 510(k) K240728 | Oncology, AIBiology & IVD Commercialization Market Watch | Bristol Myers Squibbs Cobenfy Faces Uptake Challenges Amid Strong Q3 Earnings Bristol Myers Squibb ($BMY) reported $12.2B in Q3 revenue, surpassing analyst expectations yet investor attention centered on Cobenfy, the first new schizophrenia drug in 35 years, which posted $43M in sales, slightly below forecasts
Eli Lilly and Company, and Novo Nordisk are key players in GLP-1 agonists market
The peptide was first synthesized by researchers investigating cytoprotective proteins found in gastric juice
Erectile dysfunction treatment typically begins with PDE5 inhibitors such as sildenafil or tadalafil
Increasing prescriptions of GLP-1 RAs in adolescents These data indicate a substantial rise in AOM semaglutide, following its approval for adolescent obesity management in late 2022 ( 6 )
